|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date27 Sep 2012 |
A Phase 1b Study of the Multi-Kinase Inhibitor Regorafenib in Combination With the BCL-2 Inhibitor Venetoclax Plus Azacitidine in Patients With Relapsed/Refractory Acute Myeloid Leukemia
This phase Ib trial tests the safety, side effects, best dose and effectiveness of regorafenib in combination with venetoclax and azacitidine in treating patients with acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Regorafenib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps to slow or stop the spread of cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells. Giving regorafenib in combination with venetoclax and azacitidine may be safe, tolerable and/or effective in treating patients with relapsed or refractory AML.
100 Clinical Results associated with DDR2 x VEGFR1 x FGFR2 x VEGFR2 x RET x MAPK11 x FGFR1 x BRAF x CRAF x PDGFRβ x FRK x BRAF V600E x PDGFRα x ABL x c-Kit x TrkA x VEGFR3 x CSF-1R x Tie-2 x EphA2
100 Translational Medicine associated with DDR2 x VEGFR1 x FGFR2 x VEGFR2 x RET x MAPK11 x FGFR1 x BRAF x CRAF x PDGFRβ x FRK x BRAF V600E x PDGFRα x ABL x c-Kit x TrkA x VEGFR3 x CSF-1R x Tie-2 x EphA2
0 Patents (Medical) associated with DDR2 x VEGFR1 x FGFR2 x VEGFR2 x RET x MAPK11 x FGFR1 x BRAF x CRAF x PDGFRβ x FRK x BRAF V600E x PDGFRα x ABL x c-Kit x TrkA x VEGFR3 x CSF-1R x Tie-2 x EphA2